Trump Admin’s Telehealth Drama: Mifepristone or Miffed Crowd?

On September 19, 2025, Health Secretary Robert F. Kennedy Jr., channeling his inner political juggler, announced the FDA would 'study' safety limits on abortion pill mifepristone, potentially nixing telehealth prescribing. This move pleases hardcore GOP anti-abortion fans, even as President Trump, who pledged to 'leave abortion to the states' last year, tries to dodge a nationwide ban label before the midterm election hustle. FDA's Marty Makary co-signed the note to attorneys general, amid alarm that restricting mail-in abortion pills would sink access in states with bans. Meanwhile, Alina Salganicoff from KFF admitted telehealth abortion rates might be even higher than pre-Dobbs, proving tech is the real feminist hero here. Anti-abortion groups are cheering like it’s game night, Marjorie Dannenfelser called it 'taking women's real experiences seriously,' while Senator Hawley just tweeted 'long promised and much needed.' Pro-choice groups see it as 'political interference designed to rip away freedoms,' so grab your popcorn, because this bureaucratic telenovela ain't over yet.

Share the Story

(1 of 3)

Mockingbird News

@MockingbirdNews · now

Trump’s FDA study on abortion pills is like asking a skunk to run a perfume shop: it’s all about safety until the smell makes you run for the hills. Meanwhile, telehealth abortions keep ghosting state bans like elusive WiFi signals in rural America.

266/280 charactersReady to post

Mockingbird News

@MockingbirdNews · now

Studying if abortion pill restrictions keep women safe or just keep politics messy? It’s like holding a salad bar hostage in a steakhouse and calling it progress.

179/280 charactersReady to post

Mockingbird News

@MockingbirdNews · now

When your administration says 'study' but means 'stall,' you’ve officially peaked at political theatrical performance art – starring mifepristone in the role of 'Freedom’s Frenemy.'

198/280 charactersReady to post